摘要
目的 观察调强放疗联合吉西他滨在局部晚期非小细胞肺癌（NSCLC）患者中的近期疗效。方法 回顾性分析局部晚期NSCLC患者45例临床资料。予吉西他滨加顺铂方案诱导化疗2个周期后，分为调强放疗序贯吉西他滨加顺铂方案化疗组和吉西他滨加顺铂方案单纯化疗组。结果 序贯组客观缓解率为65.2 %（15／23），单独化疗组客观缓解率为31.8 %（7／22），差异有统计学意义（P＜0.05）；序贯组和单纯化疗组1年生存率分别为66.4 %和45.0 %，两组间差异有统计学意义（P＜0.05）。结论 调强放疗序贯吉西他滨加顺铂方案化疗治疗局部晚期NSCLC较吉西他滨加顺铂方案化疗的近期疗效好，不良反应可以耐受。
Objective To evaluate the recent effects of IMRT plus gemcitabine for locally advanced non-small-cell lung cancer. Methods The data of forty-five patients were retrospectively reviewed. The treatment group consisted of 23 cases, treated with sequential same chemotherapy regimens and IMRT, the control group consisted of 22 cases, receiving same chemotherapy regimens after two cycles of gemcitabine and cisplatin induction chemotherapy. Resuls The remission rates were 65.2 % （15/23） and 31.8 % （7/22） respectively in treatment and control group. The 1 year survival rates were 66.4 % and 45.0 % respectively in treatment and control group. The remission rates and 1 year survival rates were significant different between two groups （both P 〈 0.05）. Conclusion The short-term effect of sequential chemotherapy and IMRT is better than chemotherapy and the adverse events can be better tolerated.
出处
《肿瘤研究与临床》
CAS
2014年第2期91-93,97,共4页
Cancer Research and Clinic
关键词
调强放疗
化疗
非小细胞肺癌
序贯
癌
非小细胞肺
放射疗法
计算机辅助
药物疗法
联合
IMRT, Chemotherapy, Non-small cell lung cancer, sequential Carcinoma, non-small-cell lung Radiotherapy, computer-assisted Drug therapy, combination
